Clinical Scorecard: Hydrus: The Long-Term Evidence
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Reduction of intraocular pressure (IOP) and medication usage when combined with cataract surgery. |
| Target Population | Patients undergoing cataract surgery with glaucoma. |
| Care Setting | Ophthalmology clinics and surgical centers. |
Key Highlights
- 77.2% of Hydrus patients achieved an unmedicated IOP reduction of ≥20% from baseline at 24 months.
- 59% of Hydrus patients remained entirely medication-free at five years.
- Hydrus significantly reduced day-one postoperative IOP spikes (1.4% vs. 14.4% in control).
- Fewer patients in the Hydrus group required later incisional glaucoma surgery over five years.
- Long-term follow-up enhances reliability and robustness of data.
Guideline-Based Recommendations
Diagnosis
- Evaluate IOP and medication usage in glaucoma patients preoperatively.
Management
- Consider Hydrus Microstent implantation during cataract surgery for glaucoma management.
Monitoring & Follow-up
- Follow up on IOP levels and medication needs at regular intervals post-surgery.
Risks
- Monitor for postoperative IOP spikes, especially on day one.
Patient & Prescribing Data
Patients with glaucoma undergoing cataract surgery.
Hydrus Microstent may reduce the need for additional glaucoma surgeries and medication.
Clinical Best Practices
- Wash out medications before measuring IOP to assess true surgical effect.
- Educate patients on the potential benefits of Hydrus in reducing medication dependency.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
